Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 02, 2024
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 07, 2024
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 21, 2023
FDA Approval Summary: Belzutifan for VHL Disease Tumors-Response.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 04, 2022
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
Journal: European urology
Published: October 27, 2022
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 04, 2022
Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.
Journal: Vascular medicine (London, England)
Published: April 12, 2021
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 03, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 23, 2019
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 12, 2016
U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Journal: The oncologist
Published: April 23, 2015
Last Updated: 09/26/2026